Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[O‑Phosphono‑Pyridoxyl]‑Isoleucine is an experimental small molecule compound structurally related to pyridoxamine 5'-phosphate and isoleucine. It has been studied primarily as a biochemical probe and inhibitor in research settings, particularly for its interaction with aminotransferase enzymes such as human mitochondrial branched chain aminotransferase (hBCATm). The compound mimics the structure of enzyme intermediates involving pyridoxal phosphate and amino acids, allowing it to act as a competitive inhibitor or mechanistic probe in enzymology studies. There are no approved therapeutic indications or clinical uses for this molecule[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[O-Phosphono-Pyridoxyl]-Isoleucine.